Benitec Biopharma

Benitec Biopharma Benitec Biopharma holds the dominant global patent position for expressed RNA interference.

Benitec Biopharma was founded in 1997 and has been publicly listed on the ASX since then. During the mid 2000's, Benitec was involved in a lengthy and ultimately successful patent litigation, which included defense of our platform technology patents. This action resulted in their being re-examined and re-issued in all jurisdictions by 2012. Benitec Biopharma is developing therapeutic agents in-hou

se for use with human conditions of high prevalence and value. In addition, we out-license our proprietary technology to biotechnology and biopharma companies for use in non-core therapeutic areas, such as HIV/AIDS, Retinitis Pigmentosa, Huntington's Disease, and human cancer vaccines. We also licence the technology as a research agent and cross-license in other situations.

Address

Hayward, CA
94545

Alerts

Be the first to know and let us send you an email when Benitec Biopharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Benitec Biopharma:

Share